For instance, we detected key actionable mutations, such as KRAS G12C and EGFR T790M, exclusively in plasma in certain stage III cases, underscoring the importance of combining liquid biopsy with tissue biopsy for more comprehensive lung cancer management. This evidence concerns the gene KRAS and lung carcinoma.